Hepatitis Forums

Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on December 11, 2020, 09:45:56 am

Title: Egrifta Improves Liver Health in People With HIV
Post by: Hep Editors on December 11, 2020, 09:45:56 am

Egrifta (tesamorelin), a growth hormone–releasing factor analogue, turns off genes that promote inflammation and scar tissue buildup in people living with HIV who have non-alcoholic fatty liver disease (NAFLD), thereby improving their liver health and potentially reducing the risk of liver cancer, according to a recent study.

“These data demonstrate for the first time how tesamorelin reduces the accumulation of liver fat and improves hepatic gene expression that reflect an overall return toward liver health in people living with HIV-associated NAFLD/NASH,” Steven Grinspoon, MD, of Massachusetts General Hospital, said in a press release from Theratechnologies.

For more...
https://www.hepmag.com/article/egrifta-improves-liver-health-people-hiv